Stock Analysis

Haoxi Health Technology Full Year 2024 Earnings: EPS: US$0.04 (vs US$0.035 in FY 2023)

NasdaqCM:HAO
Source: Shutterstock

Haoxi Health Technology (NASDAQ:HAO) Full Year 2024 Results

Key Financial Results

  • Revenue: US$48.5m (up 72% from FY 2023).
  • Net income: US$1.29m (up 33% from FY 2023).
  • Profit margin: 2.7% (down from 3.4% in FY 2023). The decrease in margin was driven by higher expenses.
  • EPS: US$0.04 (up from US$0.035 in FY 2023).
earnings-and-revenue-history
NasdaqCM:HAO Earnings and Revenue History October 31st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Haoxi Health Technology shares are up 8.9% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 3 warning signs for Haoxi Health Technology you should know about.

Valuation is complex, but we're here to simplify it.

Discover if Haoxi Health Technology might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.